Soligenix

Soligenix Equity Growth

The Year-over-Year Equity Growth of Soligenix (SNGX) as of Oct 17, 2026 is 28.51 %. In the previous year, Year-over-Year Equity Growth was 63.26 % — a change of -54.93% (lower).

Equity Growth

28.51 %

YoY

-54.93%

Last updated:

Year-over-Year Equity Growth of Soligenix is 2025 28.51 % . Year-over-Year Equity Growth of Soligenix was 2024 63.26 % . It decreases by -54.93% lower compared to the previous year.

The Soligenix Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
-0.63 USD
Jan 1, 2019
-76.80 USD
Jan 1, 2020
156.79 USD
Jan 1, 2021
186.56 USD
Jan 1, 2022
-123.04 USD
Jan 1, 2023
202.09 USD
Jan 1, 2024
63.26 USD
Jan 1, 2025
28.51 USD
The Soligenix Equity Growth history
YEAREquity GrowthYoY
28.51 %-54.93%
63.26 %-68.70%
202.09 %-264.24%
-123.04 %-165.95%
186.56 %+18.98%
156.79 %-304.16%
-76.80 %+12,174.04%
-0.63 %-95.70%
-14.57 %-100.04%
40,502.25 %+45,871.76%
88.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Year-over-Year Equity Growth of Soligenix is 28.51 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Soligenix since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Soligenix

All Key Metrics — Soligenix